NR1H4 and metabolic dysfunction-associated steatotic liver disease: Decreased FXR activity attenuates suppression of SREBP1c‐mediated lipogenesis and dysregulates CYP7A1 expression, collectively promoting hepatic lipid accumulation, inflammation, and MASLD progression [168].